Tumor-specific plasma DNA

Tumor-specific plasma DNA
NCT01617915
This study explores the potential of using tumor-derived DNA in the bloodstream as a quantitative biomarker of tumor burden and response to chemotherapy in women with triple-negative or HER2+ breast cancer, or patients with lung cancer.